Al's Comment:

Very exciting news.  As I mentioned in a few previous posts (such as https://virtualtrials.org/newsarticle.cfm?item=6750) , the G47 Delta virus did remarkably well in a phase 2 trial for recurrent or residual Glioblastoma.  They reported a 1 year survival rate of 92% compared to historical controls of 15%.  This article says they applied for the Japanese equivalent of our FDA approval for it last month.   So at least in Japan, there will hopefully be a new, effective  Glioblastoma treatment soon. We have to work on getting it here in the USA.


Posted on: 01/06/2021

Daiichi Sankyo Submits Application for Oncolytic Virus Teserpaturev (G47 Delta) for Treatment of Patients with Malignant Glioma in Japan

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!